1. Home
  2. All press releases

Start of the first Phase II clinical trial with monoclonal antibody IPH 2101 supported by a new 2.9 million euros financing from Oséo

  • Approval by the French regulatory authorities of a first Phase IIa clinical trial with IPH 2101 in patients suffering from Multiple Myeloma, a severe haematological cancer
  • Conducted in France, this multicenter trial will be supported by a 2.9 million euros grant from Oséo
  • Other Phase IIa trials with IPH 2101 are being planned
PR in english 44.2 KB
CP en français 45.24 KB